Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

Texas MPN Workshop 2022 | The value of add-on therapy approaches in MF

Naveen Pemmaraju • 27 Aug 2022
Texas MPN Workshop 2022
Myelofibrosis Myeloproliferative Neoplasms Navitoclax Parsaclisib Pelabresib

Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the benefits of combining a second agent with a JAK inhibitor when treating patients with myelofibrosis (MF), and further highlights some agents being explored, including navitoclax, pelabresib, and parsaclisib. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Naveen Pemmaraju

The value and interactive format of the MPN Workshop of the Carolinas 6:05
The value and interactive format of the MPN Workshop of the Carolinas
Naveen Pemmaraju et al. • 22 Aug 2025
An update on the CADENZA study: investigating pivekimab sunirine in patients with BPDCN 2:06
An update on the CADENZA study: investigating pivekimab sunirine in patients with BPDCN
Naveen Pemmaraju • 15 Jun 2025
Promising approaches being explored in BPDCN: targeting CD123, BCL2, combination therapies & more 1:55
Promising approaches being explored in BPDCN: targeting CD123, BCL2, combination therapies & more
Naveen Pemmaraju • 31 May 2025
A review of the clinical safety and efficacy of ruxolitinib 10 years after its approval for PV 2:17
A review of the clinical safety and efficacy of ruxolitinib 10 years after its approval for PV
Naveen Pemmaraju • 31 May 2025

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals